Nanocarrier formulated enzyme for the treatment of S. aureus infection

Award Information
Agency:
Department of Health and Human Services
Amount:
$600,000.00
Program:
SBIR
Contract:
1R43AI098130-01A1
Solitcitation Year:
2012
Solicitation Number:
PA10-123
Branch:
N/A
Award Year:
2012
Phase:
Phase I
Agency Tracking Number:
R43AI098130
Solicitation Topic Code:
NIAID
Small Business Information
PHARMAIN CORPORATION
19805 N. Creek Pkwy, Suite 200, Bothell, WA, -
Hubzone Owned:
N
Woman Owned:
N
Socially and Economically Disadvantaged:
N
Duns:
167580682
Principal Investigator
 GERARDO CASTILLO
 (206) 568-1499
 gcastillo@pharmain.com
Business Contact
 MELISSA KILCUP
Phone: (206) 451-7105
Email: gms@pharmain.com
Research Institution
 Stub
Abstract
DESCRIPTION (provided by applicant): Lyso, a metalloendopeptidase that is bacteriolytic for S. aureus, is a potential systemic therapy for treating methicillin-resistant S. aureus (MRSA) mediated infections including endocarditis, osteomyelitis, catheter related infections, and MRSA-mediated community acquired furunculosis and pneumonia. However, the short half-life of this enzyme in vivo has precluded its development thus far as a systemic therapy, despite positive clinical trial data. Our company, PharmaIN, has developed a nanocarrier, Protected Graft Copolymers (PGC), that can reversibly bind peptides and/or proteins (US patent #7,138,105) with measurable dissociation constant (Kd). Importantly, because of its size, PGC nanocarrier concentrates at sites of increased vascular permeability and thus can potentially concentrate lyso at the site of infection. Our goal is to develop a formulation of lyso to provide life-saving treatment against MRSA and to suppress the emergence of resistance. Our preliminary data demonstrates that PGC can reversibly associate with lyso, increase blood half-life 14-fold, and increase its in vivo efficacy against MRSA by 100-fold. We propose to prepare endotoxin- free lyso and create a master cell-line bank (E. coli expressing lyso) that will be used for: 1) this project to supply our lyso needs, and 2) as reference cells for the planned post-SBIR IND filing and clinical trial. We will also optimize the structure of PGC by synthesizing variations (at least 10) of the effectivePGC shown in the preliminary data with the intention to further extend the half-life to at least 30 fold. This is important before we put a lot of resource towards IND. To this end, we will continue the development of PGC-lyso formulation by doing bindingstudies of at least 10 new carrier variations. We will do PKs and biodistribution studies on at least 6 selected lyso formulations. We will determine and compare with commercially available antibiotics the effectiveness of our lyso formulation in vivo against MRSA. PharmaIN Corp. Confidential PUBLIC HEALTH RELEVANCE: We will develop a formulation of lysostaphin (lyso) to provide a life-saving treatment against MRSA and to suppress the emergence of resistance. To this end, we will optimize the structure of PGC to extend lyso blood residence time by 30 fold and effectiveness in vivo against MRSA by more than 100-fold. We also propose to prepare endotoxin-free lyso and create a master cell-line bank (E. coli expressing lyso) that will be used for:1) this project to supply our lyso needs, and 2) as reference cells for the planned post-SBIR IND filing and clinical trial. PharmaIN Corp. Confidential

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government